In November 2023, a new GLP-1, called tirzepatide (Zepbound, Mounjaro), was approved for weight loss and obesity management
Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity), along with tirzepatide (Mounjaro, Zepbound)a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonistare effective medications for type 2 diabetes and weight management
Can constipation interfere with liver detoxification
New faculty explore how individual minds influence group behavior Your sarcasm is showingand its history is surprisingly violent Delphine Dahan of the School of Arts & Sciences says, It feels so hard to be on the receiving end of sarcasm.